MSA-VT Score for Assessment of Long-Term Prognosis after Electrical Storm Ablation

Prognosis after electrical storm (ES) ablation remains severe, especially in patients with recurrent sustained monomorphic ventricular tachycardia (SMVT) or progressive heart failure (HF). However, single-factor-based prediction is suboptimal and may be refined by more complex algorithms. We sought...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biomedicines 2024-02, Vol.12 (3), p.493
Hauptverfasser: Vatasescu, Radu, Cojocaru, Cosmin, Gondos, Viviana, Iorgulescu, Corneliu, Bogdan, Stefan, Onciul, Sebastian, Berruezo, Antonio
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Prognosis after electrical storm (ES) ablation remains severe, especially in patients with recurrent sustained monomorphic ventricular tachycardia (SMVT) or progressive heart failure (HF). However, single-factor-based prediction is suboptimal and may be refined by more complex algorithms. We sought to evaluate if a novel score MSA-VT (M = moderate/severe mitral regurgitation, S = severe HF at admission, A = atrial fibrillation at admission, VT = inducible SMVT after ablation) may improve prediction of death and recurrences compared to single factors and previous scores (PAINESD, RIVA and I-VT). A total of 101 consecutive ES ablation patients were retrospectively analyzed over a 32.8-month (IQR 10-68) interval. The MSA-VT score was calculated as the sum of the previously mentioned factors' coefficients based on hazard ratio values in Cox regression analysis. The AUC for death prediction by MSA-VT was 0.84 ( < 0.001), superior to PAINESD (AUC 0.63, = 0.03), RIVA (AUC 0.69, = 0.02) and I-VT (0.56, = 0.3). MSA-VT ≥ 3 was associated with significantly higher mortality during follow-up (52.7%, < 0.001). Prediction by single factors and previously published scores after ES ablation may be improved by the novel MSA-VT score; however, this requires further external validation in larger samples.
ISSN:2227-9059
2227-9059
DOI:10.3390/biomedicines12030493